The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Aberrant response in vitro of hormone‐responsive prostate cancer cells to antiandrogens
Abstract
Antiandrogens are in use alone and in combination with other agents as hormonal therapy for prostate cancer. We conducted studies on the androgen‐responsive human prostate cancer cell line LNCaP to determine the direct effects of three antiandrogens (hydroxyflutamide, RU23908, and cyproterone acetate) on hormone‐responsive human prostate cancer cells in culture. Dihydrotestosterone (DHT) stimulated the growth of LNCaP cells in a dose‐dependent fashion. These cells contained approximately 31,000 high‐affinity (Kd = 9 × 10−10 M) androgen binding sites per cell. In the absence of any androgenic stimulation, all three antiandrogens tested showed agonistic properties by increasing the cell number and uptake of [3 H]‐thymidine. Competitive uptake studies using [3 H]‐R1881, a nonmetabolized androgen, showed that the three antiandrogens inhibited specific R1881 uptake with IC50s of 0.9 × 10−7 M for hydroxyflutamide, 2 × 10−7 M for RU23908, and 1 × 10−7 M for cyproterone acetate. It is not known whether these unexpected agonistic effects are due to an altered receptor, previously unmasked agonistic properties of the antiandrogens, or emergence of a hypersensitive clone of cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Simard, J., Luthy, I., Guay, J., Bélanger, A., & Labrie, F. (1986) · Molecular and Cellular Endocrinology · doi:10.1016/0303-7207(86)90132-2 · Cited by 256
Cited by
Androgen Receptor in Prostate Cancer
Heinlein, C. A., & Chang, C. (2004) · Endocrine Reviews · doi:10.1210/er.2002-0032 · Cited by 1,780
Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Berrevoets, C., Claassen, E., van Rooij, H. C. J., Trapman, J., Brinkmann, A. O., & Mulder, E. (1990) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(05)80067-1 · Cited by 950
Molecular Biology of the Androgen Receptor
Gelmann, E. P. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.018 · Cited by 942
Self-citationVeldscholte, J., Berrevoets, C. A., Ris-Stalpers, C., Kuiper, G. G. J. M., Jenster, G., Trapman, J., Brinkmann, A. O., & Mulder, E. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90401-4 · Cited by 446
Culig, Z. (1993) · Molecular Endocrinology · doi:10.1210/me.7.12.1541 · Cited by 440
Kemppainen, J. A., Lane, M. V., Sar, M., & Wilson, E. M. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)48380-9 · Cited by 430
Mechanisms Underlying the Development of Androgen-Independent Prostate Cancer
Pienta, K. J., & Bradley, D. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0067 · Cited by 430
Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., Bartsch, G., Utermann, G., Schneider, M. R., Parczyk, K., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690684 · Cited by 409
Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.
Scher, H. I., & Kelly, W. K. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.8.1566 · Cited by 405
Tan, J.-A. (1997) · Molecular Endocrinology · doi:10.1210/me.11.4.450 · Cited by 375
Androgen deprivation therapy for prostate cancer: Current status and future prospects
Miyamoto, H., Messing, E. M., & Chang, C. (2004) · The Prostate · doi:10.1002/pros.20115 · Cited by 317
Environmental antiandrogens: developmental effects, molecular mechanisms, and clinical implications
Kelce, W. R., & Wilson, E. M. (1997) · Journal of Molecular Medicine · doi:10.1007/s001090050104 · Cited by 309
p53 oncogene mutations in three human prostate cancer cell lines
Carroll, A. G., Voeller, H. J., Sugars, L., & Gelmann, E. P. (1993) · The Prostate · doi:10.1002/pros.2990230206 · Cited by 303
Self-citationVeldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A., & Mulder, E. (1992) · Biochemistry · doi:10.1021/bi00123a026 · Cited by 282
Autologous Down-Regulation of Androgen Receptor Messenger Ribonucleic Acid
Quarmby, V. E., Yarbrough, W. G., Lubahn, D. B., French, F. S., & Wilson, E. M. (1990) · Molecular Endocrinology · doi:10.1210/mend-4-1-22 · Cited by 268
From estrogen to androgen receptor: A new pathway for sex hormones in prostate
Yeh, S., Miyamoto, H., Shima, H., & Chang, C. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.10.5527 · Cited by 267
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
Aurilio, G., Cimadamore, A., Mazzucchelli, R., Lopez-Beltran, A., Verri, E., Scarpelli, M., Massari, F., Cheng, L., Santoni, M., & Montironi, R. (2020) · Cells · doi:10.3390/cells9122653 · Cited by 258
Yoon, H.-G., & Wong, J. (2006) · Molecular Endocrinology · doi:10.1210/me.2005-0324 · Cited by 120
Androgen Receptor Mutations in Carcinoma of the Prostate: Significance for Endocrine Therapy
Culig, Z., Klocker, H., Bartsch, G., & Hobisch, A. (2001) · American Journal of PharmacoGenomics · doi:10.2165/00129785-200101040-00001 · Cited by 50
Metadata
- Authors
- Wilding, G., Chen, M., & Gelmann, E. P.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 1989-01
- Volume
- 14
- Issue
- 2
- Pages
- 103-115
- ISSN
- 0270-4137 (ISSN-L)
- 1097-0045
- OpenAlex
- W2142365640
- Cited by
- 205
- References
- 1
- FWCI
- 14.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.